Beyond Systemic RLT: Phase 2 Evidence of Local Alpha Therapy to Prevent Peritoneal Recurrence
- Limitations of systemic radioligand therapies in addressing microscopic peritoneal disease
- Scientific and clinical rationale for intraperitoneal delivery of alpha-emitting radiopharmaceuticals
- Development strategy for Radspherin® targeting prevention of peritoneal recurrence following surgery